A Phase 1/2 interventional study of VXA-G1.1-NN and Placebo Tablets in Norovirus Infections, sponsored by Vaxart. Completed at 1 site in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-05.
Sponsored by Vaxart · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Caliciviridae Infections with a site in United States — none open to participants now, none under way, none of them phase 3. Caliciviridae Infections · United States.
Among the 11 studies in Caliciviridae Infections with a site in United States, this one has the largest enrollment, is one of 3 that started in 2021, is one of 3 in phase 1/2, and was the 9th registered.
20 studies on the registry are indexed under Caliciviridae Infections; 2 are open to participants now.
Browse Caliciviridae Infections studies →None of the 11 studies in Caliciviridae Infections with a site in United States is open now. The open studies under Caliciviridae Infections, anywhere →
Of the 2 Caliciviridae Infections studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 4
First in 2011; this study’s year is marked. 3 started in 2021.
This study's enrollment of 165 is above the median of 71 across 18 interventional studies indexed under Caliciviridae Infections.
Median enrollment 60 across the 11 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 4 most frequent:
Vaxart is the lead sponsor of 23 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 6 (43%) have results posted.
Vaxart has 8 studies filed under Caliciviridae Infections — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Caliciviridae Infections with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2b randomized, double-blind, placebo-controlled vaccination and challenge study to assess the protective efficacy of the Vaxart Norovirus vaccine (VXA-G1.1-NN). Healthy adults will be randomized in a 1:1 ratio to receive one oral dose of vaccine or placebo.
Approximately 28 days post-vaccination, subjects will be admitted to an isolation ward and challenged with the NV GI.1 Norwalk challenge strain. After challenge, subjects will be monitored for signs and symptoms of acute gastroenteritis (AGE) from Day 29 to discharge. At 4 days post challenge (Day 33) asymptomatic subjects will be discharged from the isolation ward and will be followed in a series of outpatient visits and telephone calls. Symptomatic subjects may be kept in the isolation ward for up to an additional 3 days.
Study Population Healthy male and female adult volunteers age 18 to 49 years inclusive with blood type O or A and who are confirmed H type-1 antigen secretory positive Investigational Product
Active Vaccine:
Placebo Control:
Viral Challenge Inoculum
Study Hypothesis Norovirus vaccine (VXA-G1.1-NN) will protect against Norovirus Gastroenteritis (NVG) related to norovirus (NoV) infection in the challenge model
Approximately 120 subjects will be dosed in the vaccination phase to ensure at least 100 subjects (\~ 50 VXA-G1.1-NN vaccine and 50 placebo) are available to participate in the challenge phase. Approximately 28 days post-vaccination, subjects will be admitted to an isolation ward and challenged with the NV GI.1 Norwalk challenge strain. After challenge, subjects will be monitored for signs and symptoms of acute gastroenteritis (AGE) from Day 29 to discharge. NV illness lasts 2-4 days and is self-limited. At 4 days post challenge (Day 33) asymptomatic subjects will be discharged from the isolation ward and will be followed in a series of outpatient visits and telephone calls. Symptomatic subjects may be kept in the isolation ward for up to an additional 3 days.
The following study visits and remote contacts will be conducted during the study
Vaccination Phase:
Challenge Phase:
Safety Follow-Up:
An independent Safety Monitoring Committee (SMC) will convene at pre-defined intervals during the norovirus challenge period, and also ad hoc as needed during the vaccination and challenge periods, to oversee the safety of the study.
Inclusion Criteria:
Female participants must have a negative pregnancy test at pre-vaccination and pre-challenge and fulfill one of the following Criteria:
i. A reliable form of contraception must be approved by the Investigator (eg, double barrier method, Depo-Provera, intrauterine device, Norplant, oral contraceptives, contraceptive patches) d. Not be sexually active (abstinent) or in a same sex relationship (must be discussed with site staff and documented)
Exclusion Criteria:
Any of the following history or conditions that may lead to higher risk of clotting events and/or thrombocytopenia:
Presence of any of the following conditions known to increase risk of thrombosis within 6 months prior to screening:
Any one of the following ECG findings within 45 days prior to vaccination:
Exclusionary ECG findings:
History of irritable bowel disease or inflammatory digestive or gastrointestinal condition that could affect the distribution / safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine.
Such conditions may include but are not limited to:
Other conditions, in the clinical judgment of the investigator, that would jeopardize the safety or rights of a subject or interfere with the evaluation of the study
Social/Occupational:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receiving Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant
Biological: VXA-G1.1-NN · Biological: Norovirus GI.1 Norwalk Virus Inoculum
Subject receiving Placebo oral tablets similar in appearance and number to active vaccine tablets
Other: Placebo Tablets · Biological: Norovirus GI.1 Norwalk Virus Inoculum
Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant
Oral tablets similar in appearance and number to active vaccine tablets
Norwalk Virus Inoculum Lot 01-09NV
Number of Participants Who Experienced Norovirus Gastroenteritis (NVG)
NVG is a composite endpoint defined as meeting both the definition of AGE and NV. AGE was defined as meeting any one of 3 criteria (diarrhea, vomiting, or diarrhea and vomiting) in any 24-hr rolling period. The individual criteria for diarrhea, vomiting, or diarrhea and vomiting were as follows: 1\. Diarrhea: i. ≥ 3 loose or liquid stools in any 24-hr rolling period, or ii. 400 g of loose or liquid stools in any 24-hr rolling period 2. Vomiting: ≥ 2 vomiting episodes in any 24-hr rolling period, or 3. Diarrhea and vomiting: i. one vomiting episode plus any loose or liquid stool in any 24-hr rolling period ii. one vomiting episode plus ≥ 2 of the following events in any 24-hr rolling period: 1. nausea 2. fever (oral temperature ≥ 37.6°C) 3. abdominal cramps or pains 4. abdominal gurgling or bloating 5. myalgia NV infection was defined as having 1 or more positive results in stool or urine by quantitative real time reverse transcription polymerase chain reaction (qRT-PCR).
Time frame: Up to approximately Day 57
Levels of Viral Protein 1, Major Capsid, or Surface Protein of Viruses (VP1)-Specific Immunoglobulin A (IgA) Antibody-Secreting Cell (ASC) Against Norwalk at Day 8
Blood samples were collected at different timepoints throughout the study.
Time frame: Day 8
Geometric Mean Titer (GMT) of Histo-blood Group Antigen (HBGA) Blocking Antibodies Against NV by Blocking Titer 50 (BT50) at Day 28
Blood samples were collected at different timepoints throughout the study. A positive change indicates an increase in titers.
Time frame: Day 28
VP1-specific Serum Immunoglobulin G (IgG) Response at Day 28
Blood samples were collected at different timepoints throughout the study.
Time frame: Day 28
VP1-specific Serum IgA at Day 28
Blood samples were collected at different timepoints throughout the study.
Time frame: Day 28
Number of Participants Who Experienced Solicited Symptoms of Reactogenicity
Solicited symptoms of reactogenicity included: * Gastrointestinal reactions: nausea, vomiting, diarrhea and abdominal pain * Systemic reactogenicity: malaise/fatigue, anorexia, fever, headache and myalgia
Time frame: Up to Day 8
Number of Participants Who Experienced Unsolicited Adverse Events (AEs) During the Vaccination Phase
Unsolicited AEs referred to any AEs that occurred during a clinical trial but were not specifically pre-defined or actively sought by the study protocol. Unsolicited AEs could include any medical condition or symptom, whether or not it was related to the intervention being studied.
Time frame: Up to Day 28 of Vaccination Phase (28-days phase)
Number of Participants Who Experienced Serious AEs (SAEs), AEs of Specific Interest (AESIs), and New Onsets of Chronic Illness (NOCIs)
A SAE was any AE that resulted in one or more of the following outcomes: death, a life-threatening event where the subject was at immediate risk of death (not hypothetically), inpatient hospitalization or the prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of normal life functions, congenital abnormality or birth defect, or an important medical event that, that jeopardized the participant's health or required medical or surgical intervention to prevent a serious outcome. A NOCI was defined as the diagnosis post-study drug administration of a new medical condition, which was chronic in nature, including those potentially controllable by medication (e.g., diabetes, asthma).
Time frame: Up to approximately 12 months post vaccination
Number of Participants Who Experienced Unsolicited AEs During the Challenge Phase
Unsolicited AEs referred to any AEs that occurred during a clinical trial but were not specifically pre-defined or actively sought by the study protocol. Unsolicited AEs could include any medical condition or symptom, whether or not it was related to the intervention being studied.
Time frame: Up to Day 29 of Challenge Phase (28-days phase)
Number of Participants With AGE During the Inpatient Challenge Phase
AGE was defined as meeting any one of 3 criteria (diarrhea, vomiting, or diarrhea and vomiting) in any 24-hr rolling period. The individual criteria for diarrhea, vomiting, or diarrhea and vomiting were as follows: 1\. Diarrhea: i. ≥ 3 loose or liquid stools produced in any 24-hr rolling period, or ii. 400 g of loose or liquid stools produced in any 24-hr rolling period 2. Vomiting: ≥ 2 vomiting episodes in any 24-hr rolling period, or 3. Diarrhea and vomiting: i. one vomiting episode plus any loose or liquid stool in any 24-hr rolling period ii. one vomiting episode plus ≥ 2 of the following events in any 24-hr rolling period: 1. nausea 2. fever (oral temperature ≥ 37.6°C) 3. abdominal cramps or pains 4. abdominal gurgling or bloating 5. myalgia
Time frame: Day 28 of Challenge Phase (28-days phase)
Severity of AGE Assessed Using the Modified Vesikari Scale
The Modified Vesikari Scale is a tool used to assess the severity of AGE by evaluating symptoms such as diarrhea, vomiting, fever, and dehydration. It scores these symptoms based on their frequency and severity, with a minimum score of 0 and a maximum score of 20, where higher scores indicate more severe symptoms and lower scores suggest milder or no symptoms and severity.
Time frame: Up to approximately Day 36
Number of Participants Who Experienced Moderate or Severe Gastroenteritis
Moderate or severe gastroenteritis was defined by cumulative loose stools ≥ 1000gr during the inpatient period.
Time frame: Up to approximately Day 57
Duration of AGE
Time to onset of AGE was calculated as the time from challenge administration to the first recorded instance of an event satisfying the criteria for AGE. AGE was defined as meeting any of the 3 criteria: 1\. Diarrhea: i. ≥ 3 loose or liquid stools in any 24-hr rolling period, or ii. 400 g of loose or liquid stools in any 24-hr rolling period 2. Vomiting: ≥ 2 vomiting episodes in any 24-hr rolling period, or 3. Diarrhea and vomiting: i. one vomiting episode plus any loose or liquid stool in any 24-hr rolling period ii. one vomiting episode plus ≥ 2 of the following events in any 24-hr rolling period: 1. nausea 2. fever (oral temperature ≥ 37.6°C) 3. abdominal cramps or pains 4. abdominal gurgling or bloating 5. myalgia
Time frame: Up to approximately Day 57
Number of Participants Who Experienced Incidences of Diarrhea or Emesis
Classification of diarrhea was done through grading stools with Grade 3 (thick liquid stool) to Grade 5 (clear water diarrheal stool) being considered diarrhea.
Time frame: Up to approximately Day 57
Number of Participants With Norovirus (NoV) Infection up to Challenge Period Day 8
NoV infection was defined as a positive qRT-PCR in stool or emesis up to Challenge Period Day 8, and the presence of NV antigen in stool.
Time frame: Challenge Phase Day 8 (equal to Study Day 36)
Geometric Mean Genome Copies (GCs) of NoV Shedding in Stool Measured by qRT-PCR
NoV shedding was assessed by qRT-PCR. Stool samples were reported on 10\^3 copies/gm. If a participant produced multiple results for a given study day, the result with the largest shedding response was used for analysis. Samples that were reported as "Not Quantifiable" or as lower than the limit of detection (LOD) were analyzed as ½2\*LOD (76.2).
Time frame: Pre-challenge up to Day 8 of Challenge Phase (equal to Study Day 36)
Geometric Mean GCs of NoV Shedding in Emesis Measured by qRT-PCR
NoV shedding was assessed by qRT-PCR. Emesis samples were reported in 10\^3 copies/mL. If a participant produced multiple results for a given study day, the result with the largest shedding response was used for analysis. Samples that were reported as "Not Quantifiable" or as lower than the limit of detection (LOD) were analyzed as ½2\*LOD (15.3).
Time frame: Pre-challenge up to Day 8 of Challenge Phase (equal to Study Day 36)
Duration of NoV Infection
Duration of NoV Infection was defined as the time from NoV infection to the time of resolution of infection, defined as a negative qRT-PCR result not followed by a positive qRT-PCR result.
Time frame: Up to approximately Day 57
VP1 GI.1-specific Fecal IgA at Day 1, Day 28 and Day 57
Fecal samples for immunogenicity assessments were collected on Day 1 (prior to vaccination), Day 28 (1 day prior to challenge), and Day 57 (28 days post-challenge). VP1 GI.1-specific IgA antibody values were normalized by the total IgA in each sample.
Time frame: Day 1 (baseline), Day 28 and Day 57
VP1 GI.1-specific Saliva IgA at Day 1, Day 28 and Day 57
Saliva samples were collected on Day 1 (prior to vaccination), Day 28 (1 day prior to challenge), and Day 57 (28 days post-challenge). VP1 GI.1-specific IgA antibody values were normalized by the total IgA in each sample.
Time frame: Day 1 (baseline), Day 28 and Day 57
Participants were enrolled at 1 center in the United States (US) between December 2021 and October 2023.
| Milestone | VXA-G1.1-NN | Placebo |
|---|---|---|
| Started | 86 | 79 |
| Entered challenge phase | 76 | 65 |
| Completed | 52 | 42 |
| Not completed | 34 | 37 |
| Withdrew: Lost to follow-up | 0 | 3 |
| Withdrew: Study terminated by sponsor | 30 | 27 |
| Withdrew: Other | 4 | 7 |
NVG is a composite endpoint defined as meeting both the definition of AGE and NV. AGE was defined as meeting any one of 3 criteria (diarrhea, vomiting, or diarrhea and vomiting) in any 24-hr rolling period. The individual criteria for diarrhea, vomiting, or diarrhea and vomiting were as follows: 1\. Diarrhea: i. ≥ 3 loose or liquid stools in any 24-hr rolling period, or ii. 400 g of loose or liquid stools in any 24-hr rolling period 2. Vomiting: ≥ 2 vomiting episodes in any 24-hr rolling period, or 3. Diarrhea and vomiting: i. one vomiting episode plus any loose or liquid stool in any 24-hr rolling period ii. one vomiting episode plus ≥ 2 of the following events in any 24-hr rolling period: 1. nausea 2. fever (oral temperature ≥ 37.6°C) 3. abdominal cramps or pains 4. abdominal gurgling or bloating 5. myalgia NV infection was defined as having 1 or more positive results in stool or urine by quantitative real time reverse transcription polymerase chain reaction (qRT-PCR).
| Participants | VXA-G1.1-NN | Placebo |
|---|---|---|
| Number of Participants Who Experienced Norovirus Gastroenteritis (NVG) | 34 | 37 |
Blood samples were collected at different timepoints throughout the study.
| cells/10^6 PBMCs | VXA-G1.1-NN | Placebo |
|---|---|---|
| Levels of Viral Protein 1, Major Capsid, or Surface Protein of Viruses (VP1)-Specific Immunoglobulin A (IgA) Antibody-Secreting Cell (ASC) Against Norwalk at Day 8 | 79.5 (69.2 to 87.6) | 0 (0.0 to 4.6) |
Blood samples were collected at different timepoints throughout the study. A positive change indicates an increase in titers.
| Geometric mean titer | VXA-G1.1-NN | Placebo |
|---|---|---|
| Geometric Mean Titer (GMT) of Histo-blood Group Antigen (HBGA) Blocking Antibodies Against NV by Blocking Titer 50 (BT50) at Day 28 | 131.6 (101.2 to 171.2) | 33.2 (26.4 to 41.8) |
Blood samples were collected at different timepoints throughout the study.
| AU/mL | VXA-G1.1-NN | Placebo |
|---|---|---|
| VP1-specific Serum Immunoglobulin G (IgG) Response at Day 28 | 4413573.1 (3167431.7 to 6149975.6) | 700657.0 (508361.8 to 965690.5) |
Blood samples were collected at different timepoints throughout the study.
| AU/mL | VXA-G1.1-NN | Placebo |
|---|---|---|
| VP1-specific Serum IgA at Day 28 | 5555338.7 (3713874.2 to 8309863.5) | 670496.0 (450873.7 to 997097.1) |
Solicited symptoms of reactogenicity included: * Gastrointestinal reactions: nausea, vomiting, diarrhea and abdominal pain * Systemic reactogenicity: malaise/fatigue, anorexia, fever, headache and myalgia
| Participants | VXA-G1.1-NN | Placebo |
|---|---|---|
| Number of Participants Who Experienced Solicited Symptoms of Reactogenicity | 50 | 36 |
Unsolicited AEs referred to any AEs that occurred during a clinical trial but were not specifically pre-defined or actively sought by the study protocol. Unsolicited AEs could include any medical condition or symptom, whether or not it was related to the intervention being studied.
| Participants | VXA-G1.1-NN | Placebo |
|---|---|---|
| Number of Participants Who Experienced Unsolicited Adverse Events (AEs) During the Vaccination Phase | 7 | 9 |
A SAE was any AE that resulted in one or more of the following outcomes: death, a life-threatening event where the subject was at immediate risk of death (not hypothetically), inpatient hospitalization or the prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of normal life functions, congenital abnormality or birth defect, or an important medical event that, that jeopardized the participant's health or required medical or surgical intervention to prevent a serious outcome. A NOCI was defined as the diagnosis post-study drug administration of a new medical condition, which was chronic in nature, including those potentially controllable by medication (e.g., diabetes, asthma).
| Participants | VXA-G1.1-NN | Placebo |
|---|---|---|
| All SAEs | 0 | 1 |
| All AESI | 0 | 1 |
| All NOCI | 0 | 0 |
Unsolicited AEs referred to any AEs that occurred during a clinical trial but were not specifically pre-defined or actively sought by the study protocol. Unsolicited AEs could include any medical condition or symptom, whether or not it was related to the intervention being studied.
| Participants | VXA-G1.1-NN | Placebo |
|---|---|---|
| Number of Participants Who Experienced Unsolicited AEs During the Challenge Phase | 31 | 23 |
AGE was defined as meeting any one of 3 criteria (diarrhea, vomiting, or diarrhea and vomiting) in any 24-hr rolling period. The individual criteria for diarrhea, vomiting, or diarrhea and vomiting were as follows: 1\. Diarrhea: i. ≥ 3 loose or liquid stools produced in any 24-hr rolling period, or ii. 400 g of loose or liquid stools produced in any 24-hr rolling period 2. Vomiting: ≥ 2 vomiting episodes in any 24-hr rolling period, or 3. Diarrhea and vomiting: i. one vomiting episode plus any loose or liquid stool in any 24-hr rolling period ii. one vomiting episode plus ≥ 2 of the following events in any 24-hr rolling period: 1. nausea 2. fever (oral temperature ≥ 37.6°C) 3. abdominal cramps or pains 4. abdominal gurgling or bloating 5. myalgia
| Participants | VXA-G1.1-NN | Placebo |
|---|---|---|
| Number of Participants With AGE During the Inpatient Challenge Phase | 40 | 39 |
The Modified Vesikari Scale is a tool used to assess the severity of AGE by evaluating symptoms such as diarrhea, vomiting, fever, and dehydration. It scores these symptoms based on their frequency and severity, with a minimum score of 0 and a maximum score of 20, where higher scores indicate more severe symptoms and lower scores suggest milder or no symptoms and severity.
| Score on scale | VXA-G1.1-NN | Placebo |
|---|---|---|
| Severity of AGE Assessed Using the Modified Vesikari Scale | 4.2 (3.5 to 4.8) | 4.4 (3.8 to 5.1) |
Moderate or severe gastroenteritis was defined by cumulative loose stools ≥ 1000gr during the inpatient period.
| Participants | VXA-G1.1-NN | Placebo |
|---|---|---|
| Number of Participants Who Experienced Moderate or Severe Gastroenteritis | 14 | 7 |
Time to onset of AGE was calculated as the time from challenge administration to the first recorded instance of an event satisfying the criteria for AGE. AGE was defined as meeting any of the 3 criteria: 1\. Diarrhea: i. ≥ 3 loose or liquid stools in any 24-hr rolling period, or ii. 400 g of loose or liquid stools in any 24-hr rolling period 2. Vomiting: ≥ 2 vomiting episodes in any 24-hr rolling period, or 3. Diarrhea and vomiting: i. one vomiting episode plus any loose or liquid stool in any 24-hr rolling period ii. one vomiting episode plus ≥ 2 of the following events in any 24-hr rolling period: 1. nausea 2. fever (oral temperature ≥ 37.6°C) 3. abdominal cramps or pains 4. abdominal gurgling or bloating 5. myalgia
| Hours | VXA-G1.1-NN | Placebo |
|---|---|---|
| Duration of AGE | 59.0 (26.7 to 117.3) | 55.8 (28.6 to 107.1) |
Classification of diarrhea was done through grading stools with Grade 3 (thick liquid stool) to Grade 5 (clear water diarrheal stool) being considered diarrhea.
| Participants | VXA-G1.1-NN | Placebo |
|---|---|---|
| Diarrhea | 52 | 44 |
| Emesis | 28 | 33 |
NoV infection was defined as a positive qRT-PCR in stool or emesis up to Challenge Period Day 8, and the presence of NV antigen in stool.
| Participants | VXA-G1.1-NN | Placebo |
|---|---|---|
| Number of Participants With Norovirus (NoV) Infection up to Challenge Period Day 8 | 44 | 53 |
NoV shedding was assessed by qRT-PCR. Stool samples were reported on 10\^3 copies/gm. If a participant produced multiple results for a given study day, the result with the largest shedding response was used for analysis. Samples that were reported as "Not Quantifiable" or as lower than the limit of detection (LOD) were analyzed as ½2\*LOD (76.2).
| 10^3 copies/gm | VXA-G1.1-NN | Placebo |
|---|---|---|
| Pre-challenge | 76.2 (NA to NA) | 76.2 (NA to NA) |
| Challenge Phase Day 1 | 76.2 (NA to NA) | 76.2 (NA to NA) |
| Challenge Phase Day 2 | 255.1 (143.9 to 452.1) | 341.2 (165.6 to 702.7) |
| Challenge Phase Day 3 | 6238.9 (2230.9 to 17447.5) | 15833.5 (5555.2 to 45129.2) |
| Challenge Phase Day 4 | 1970.7 (637.9 to 6088.1) | 16834.9 (4817.1 to 58834.9) |
| Challenge Period Day 5 | 5412.0 (1150.7 to 25454.6) | 31096.5 (4975.1 to 194366.0) |
| Challenge Phase Day 6 | 1268.7 (0.0 to 4.2004828*10^18) | 4483.0 (0.1 to 207897355.4) |
| Challenge Phase Day 8 | 627.3 (340.0 to 1157.1) | 2737.3 (1400.4 to 5350.3) |
NoV shedding was assessed by qRT-PCR. Emesis samples were reported in 10\^3 copies/mL. If a participant produced multiple results for a given study day, the result with the largest shedding response was used for analysis. Samples that were reported as "Not Quantifiable" or as lower than the limit of detection (LOD) were analyzed as ½2\*LOD (15.3).
| 10^3 copies/mL | VXA-G1.1-NN | Placebo |
|---|---|---|
| Challenge Phase Day 2 | 58.4 (19.8 to 172.4) | 457.3 (110.2 to 1897.5) |
| Challenge Phase Day 3 | 74.5 (24.9 to 222.7) | 152.5 (43.9 to 530.3) |
| Challenge Phase Day 4 | 15.3 (NA to NA) | 15.3 (NA to NA) |
| Challenge Phase Day 5 | 15.3 (NA to NA) | 15.3 (NA to NA) |
Duration of NoV Infection was defined as the time from NoV infection to the time of resolution of infection, defined as a negative qRT-PCR result not followed by a positive qRT-PCR result.
| Hours | VXA-G1.1-NN | Placebo |
|---|---|---|
| Duration of NoV Infection | 120.1 (113.4 to 126.4) | 115.8 (109.5 to 122.2) |
Fecal samples for immunogenicity assessments were collected on Day 1 (prior to vaccination), Day 28 (1 day prior to challenge), and Day 57 (28 days post-challenge). VP1 GI.1-specific IgA antibody values were normalized by the total IgA in each sample.
| μg/mg | VXA-G1.1-NN | Placebo |
|---|---|---|
| Day 1 | 715.61 (442.64 to 1156.92) | 470.86 (316.78 to 699.89) |
| Day 28 | 1888.49 (1221.06 to 2920.74) | 444.31 (304.83 to 647.60) |
| Day 57 | 6122.41 (3891.96 to 9631.10) | 5047.07 (3000.20 to 8490.39) |
Saliva samples were collected on Day 1 (prior to vaccination), Day 28 (1 day prior to challenge), and Day 57 (28 days post-challenge). VP1 GI.1-specific IgA antibody values were normalized by the total IgA in each sample.
| μg/mg | VXA-G1.1-NN | Placebo |
|---|---|---|
| Day 1 | 0.40 (0.31 to 0.51) | 0.31 (0.27 to 0.35) |
| Day 28 | 1.15 (0.84 to 1.57) | 0.35 (0.31 to 0.40) |
| Day 57 | 1.81 (1.33 to 2.44) | 1.84 (1.41 to 2.40) |
Collected over Up to approximately 16 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VXA-G1.1-NN | 0/86 (0%) | 0/86 (0%) | 55/86 (64%) |
| Placebo | 0/79 (0%) | 1/79 (1.3%) | 47/79 (59.5%) |
| Event | VXA-G1.1-NN | Placebo |
|---|---|---|
| Deep vein thrombosisVascular disorders | 0/86 | 1/79 |
| CellulitisInfections and infestations | 0/86 | 1/79 |
| Event | VXA-G1.1-NN | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 34/86 | 33/79 |
| MalaiseGeneral disorders | 25/86 | 20/79 |
| DiarrhoeaGastrointestinal disorders | 20/86 | 12/79 |
| Abdominal painGastrointestinal disorders | 14/86 | 8/79 |
| MyalgiaMusculoskeletal and connective tissue disorders | 11/86 | 12/79 |
| NauseaGastrointestinal disorders | 13/86 | 10/79 |
| Decreased appetiteMetabolism and nutrition disorders | 10/86 | 8/79 |
Full Analysis Population (FAP): all randomized participants analyzed by randomized vaccination group assignment, who received study vaccination (active or placebo), and had available data for the specified analysis.
| Age, Continuous(years) | VXA-G1.1-NN | Placebo | Total |
|---|---|---|---|
| Mean | 36 ± 8 | 34 ± 7 | 35 ± 8 |
| Sex: Female, Male(Participants) | VXA-G1.1-NN | Placebo | Total |
|---|---|---|---|
| Female | 43 | 31 | 74 |
| Male | 43 | 48 | 91 |
| Ethnicity (NIH/OMB)(Participants) | VXA-G1.1-NN | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 37 | 33 | 70 |
| Not Hispanic or Latino | 49 | 46 | 95 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | VXA-G1.1-NN | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 5 | 8 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 21 | 14 | 35 |
| White | 54 | 54 | 108 |
| More than one race | 5 | 3 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2021 to primary completion in Apr 2023, 15 months.
Results were first posted in May 2025, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VXA-G1.1-NN